Spago Nanomedical AB (publ) (SPAGO.ST)

0.3410 -0.0170 (-4.75%) At close: 05:08PM CEST

Spago Nanomedical AB (publ)

Scheelevägen 22
Lund 223 63
Sweden
46 4 68 11 88
https://spagonanomedical.se

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mats Hansen M.Sc., Ph.D.	Chief Executive Officer	2.08M	N/A	1971
Ms. Hanna Olsson M.Sc.	Chief Financial Officer	N/A	N/A	1980
Dr. Oskar Axelsson M.Sc., Ph.D.	Head of Research & Chief Scientific Officer	N/A	N/A	1962
Mr. Paul Hargreaves	Chief Development Officer	N/A	N/A	1969

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer; and Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.

Corporate governance

Spago Nanomedical AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.